·þÎñÈÈÏß
×ðÖØ¿Æѧ ¾´Î·ÖÆ¶È ×·ÇóЧÂÊ ¹Ø°®ÉúÃü
ѧÊõ¶¯Ì¬
esballÊÀ²©¹¹½¨LOXO-292ÄÍÒ©Ë«Í»±ä¹¤³Ìϸ°ûÖêÖúÁ¦RETÒÖÖƼÁ¿ª·¢
Ðû²¼Ê±¼ä£º
2021-06-22
RET£¨Rearranged during transfection£©»ùÒòÓÚ1985ÄêÊ×´ÎÔÚÈËTÁÜ°ÍÁöϸ°ûÖз¢Ã÷£¬£¬ÇÒ±»ÅжÏΪһ¸öÔ°©»ùÒò£¬£¬RET»ùÒòλÓÚÈËÀà10ºÅ³£È¾É«Ì峤±Û£¨10q11.2£©£¬£¬±àÂëÒ»ÖÖ±£´æÓÚϸ°ûĤÉϵÄÊÜÌåÀÒ°±Ëἤø£¨RTK£©[1]¡£¡£RETÂÑ°×ÔÚ³ÉÊìÀú³ÌÖУ¬£¬ÂÑ°×Ç°Ìåͨ¹ý²î±ðµÄÑ¡ÔñÐÔ¼ôÇз½Ê½£¬£¬Ö÷ÒªÐγÉÁ½ÖÖÂÑ°×ÑÇÐÍRET-9ºÍRET-51¡£¡£RET¼¤Ã¸±»Éñ¾½ºÖÊϸ°ûϵȪԴµÄÉñı»®ÑøÉú³¤Òò×ÓGDNF¼¤»î£¬£¬GFNFÓëGFRα1Á¬ÏµÐγÉGDNF-GFRα1¸´ºÏÎ£¬´Ë¸´ºÏÎïÔÙÓëRETÁ¬ÏµÐγÉÈý¸´ºÏÌ壬£¬ÒýÆðRETµÄ¶þ¾Û»¯£¬£¬²¢ÒýÆðÀÒ°±Ëá²Ð»ù×ÔÁ×Ëữ£¬£¬´Ó¶ø¼¤»îÏÂÓÎÐźÅͨ·[2]£¬£¬°üÀ¨RAS/MARK¡¢PI3K/AKT¡¢PLCγ/PKCµÈÐźÅͨ·£¬£¬½ø¶øÒýÆðϸ°ûµÄÔöÖ³·Ö»¯¡¢Ç¨áã¡¢ÔÙÉúºÍÉú³¤µÈ[1]¡£¡£
ͼ1. a) RET¼¤Ã¸½á¹¹;b) RET¼¤Ã¸»î»¯»úÖƼ°ÐźÅͨ·¡£¡£
(ͼƬȪԴÓڲο¼×ÊÁÏ[2])
RET»ùÒòÖ°©»úÖÆ£¬£¬Ö÷ÒªÓлùÒòÈںϡ¢µãÍ»±ä¡¢»ùÒòÀ©ÔöºÍȾɫÌåÖØÅŵÈ[3]¡£¡£È¾É«ÌåµÄÖØ×é³£»£»£»£»£»£»áµ¼ÖÂRET»ùÒòÖÐÖÐÖ¹ÁѺóÓë²î±ðµÄÉÏÓλùÒò±¬·¢Èںϣ¬£¬½ø¶øÐγÉÇý¶¯Ö×Áöϸ°ûÔöÖ³µÄÈںϻùÒò¡£¡£ÔÚ1990ÄêºÍ2012ÄêÏȺóÔÚ¼××´ÏÙÈéÍ·×´°©¡¢·ÎÏÙ°©ºÍÂýÐÔËèϵ°×Ѫ²¡Öз¢Ã÷ÕâÒ»±äÒì¡£¡£ÆäÖÐÈںϻùÒòÖ÷ÒªÓУºKIF5B-RET£¨×î¶à£©£¬£¬CCDC6-RETºÍNCOA4-RET£»£»£»£»£»£»RET»ùÒòÔÚNSCLC»¼ÕßÖ÷ÒªÒÔRET»ùÒòÈÚºÏÐÎʽ±¬·¢¸Ä±ä£¬£¬Ñо¿ÏÔʾ·ÇСϸ°û·Î°©ÖÐKIF5B©\RETÈÚºÏÔ¼Õ¼ËùÓÐRETÈÚºÏµÄ 68.3 %£¬£¬Æä´ÎΪCCDC6©\RET (16.8 %)¼°NCOA4©\RET (1.2 %)[4]¡£¡£ËäÈ»RET»ùÒòÔÚNSCLC»¼ÕßÖеķ¢²¡ÂʽöΪ1.4 %-2.5 %£¬£¬¿ÉÊÇÎÒ¹úµÄ»¼Õß»ùÊýºÜÊǴ󣬣¬Òò¶øЯ´øRET»ùÒòÈںϵÄNSCLC»¼Õß²¢²»ÉÙ¼û[5]¡£¡£µãÍ»±ä¶àλÓÚGate keeper²Ð»ù£¬£¬Ö÷ÒªÊÇV804λµã£¨V804M£¬£¬V804L£©£¬£¬»¹°üÀ¨ÈܼÁÇ°ÑØÍ»±äG810λµã£¨G810R£¬£¬G810S£¬£¬G810C£¬£¬G810A£¬£¬G810V£©¡¢M918TºÍC634λµã£¨C634R£¬£¬C634G£¬£¬C634F£¬£¬C634S£¬£¬C634W£¬£¬C634Y£¬£¬C634K£©Í»±äµÈ[1]¡£¡£
ͼ2. ²î±ð°©Ö¢ÖÐRET»ùÒò¸Ä±äµÄ¸ÅÊö¡£¡£
(ͼƬȪԴÓڲο¼×ÊÁÏ[3])
ͼ3. RET»ùÒòµÄÖ÷ÒªÈںϷ½Ê½ºÍµãÍ»±äλµã¡£¡£
(ͼƬȪԴÓڲο¼×ÊÁÏ[1])
2011ÄêºÍ2013Ä꣬£¬FDAºÍEMA»®·ÖÅú×¼VandetanibºÍCabozantinibÓÃÓÚÖÎÁÆÏ£ÍûµÄÍíÆÚµÄMTC»¼Õߣ¬£¬²¢ÒÑÔÚRETÈÚºÏÑôÐÔNSCLC»¼ÕßÖÐÏÔʾ³ö»îÐÔ[1]¡£¡£µ«ÉÏÊöÒ©ÎïÕûÌå¹ØÓÚRET»ùÒòÈÚºÏÍ»±äµÄ°ÐÏòÌØÒìÐÔ²¢²»Ç¿£¬£¬Æä²»µ«ÒÖÖÆRETÂÑ°×Ðźţ¬£¬Í¬Ê±»áÒÖÖÆVEGFR¡¢EGFRµÈÆäËûÂÑ°×£¬£¬ÓÐÓÃÐÔÏà¶Ô½Ï²î£¬£¬ÇÒ¸±×÷ÓúͷǰÐÏò¶¾ÐÔÔöÌí¡£¡£2020Äê5ÔÂ9ÈÕ£¬£¬FDA¼ÓËÙÅú×¼ÁËLoxo Oncology¹«Ë¾(ÀñÀ´ÆìÏÂ)selpercatinib(LOXO-292£¬£¬Retevmo)ÉÏÊУ¬£¬ÓÃÓÚÖÎÁƲ¿·ÖRETÈںϻùÒòµÄ·ÇСϸ°û·Î°©³ÉÈË»¼Õߣ¬£¬ºÍÍíÆÚRETÍ»±äÑôÐÔ¼××´ÏÙËèÑù°©(MTC)»¼Õß¼°ÍíÆÚ»òתÒƵÄRETÈÚºÏÑôÐÔ¼××´ÏÙ°©»¼Õß¡£¡£ÕâÊÇFDAÅú×¼µÄÊ׿î¸ßÑ¡ÔñÐÔRET¼¤Ã¸ÒÖÖƼÁ¡£¡£Selpercatinib(LOXO-292)ÊÇ¿Ú·þÓÃÒ©µÄATP¾ºÕùÐÔС·Ö×ÓRET¼¤Ã¸ÒÖÖƼÁ£¬£¬Ëü¾ßÓд©Í¸ÖÐÊàÉñ¾ÏµÍ³(CNS)µÄÄÜÁ¦£¬£¬²¢ÇÒ¿ÉÒÔ°ÐÏò¼¤»îÐÔRETÈںϡ¢µãÍ»±äºÍijЩ»ñµÃÐÔÄÍÒ©Í»±ä(¶Ô°üÀ¨KIF5B-RETºÍCCDC6-RETÈÚºÏÀàÐÍ£¬£¬ÒÔ¼°RET-V804L/MºÍM918TÄÍÒ©Í»±äÃô¸Ð)[1]¡£¡£2020Äê9ÔÂ5ÈÕ£¬£¬FDAÅú×¼À¶Í¼¹«Ë¾(Blueprint Medicines Corporation)¿ª·¢µÄRETÒÖÖƼÁPralsetinib(BLU-667£¬£¬Gavreto)ÉÏÊУ¬£¬ÓÃÓÚÖÎÁÆRETÈÚºÏÑôÐÔתÒÆÐÔ·ÇСϸ°û·Î°©(NSCLC)³ÉÈË»¼Õß[1]¡£¡£2021Äê3ÔÂ24ÈÕ£¬£¬BLU667(ÆÕÀÌæÄá, ÉÌÆ·Ãû£ºÆÕ¼ª»ª®)»ñµÃÖйú¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö(NMPA)Åú×¼£¬£¬ÓÃÓÚ¼ÈÍù½ÓÊܹýº¬²¬»¯ÁƵÄRET»ùÒòÈÚºÏÑôÐԵľֲ¿ÍíÆÚ»òתÒÆÐÔNSCLC³ÉÈË»¼Õߣ¬£¬³ÉΪº£ÄÚÊ׸öÒ²ÊÇÏÖÔÚΨһ»ñÅúµÄRETÒÖÖƼÁ[1]¡£¡£
²»¹ý£¬£¬ÓÌÈçÆäËû°ÐÏòÒ©Ò»Ñù£¬£¬ÄÍÒ©ÊDz»¿É×èÖ¹µÄ¡£¡£2020Äê1ÔÂ24ÈÕ£¬£¬¡¶J Thorac Oncol¡·±¨µÀÁË2ÀýRETÈںϷÇСϸ°û·Î°©»¼ÕßÔÚʹÓÃLOXO-292ºó·ºÆðÈܼÁÇ°ÑØÍ»±ä(RET G810R/S/C)£¬£¬½ø¶øµ¼ÖÂLOXO-292ÄÍÒ©¡£¡£½á¹¹Ä£×ÓÔ¤²â£¬£¬RETÈܼÁÇ°ÑØÍ»±äG810R/S/C/VÍ»±äÔÚ¿Õ¼äÉÏ×è°ÁËSelpercatinibµÄÁ¬Ïµ£¬£¬ÌåÍâÊÔÑé֤ʵ¿¹RET¶à¼¤Ã¸ÒÖÖƼÁMKIºÍÑ¡ÔñÐÔRET TKIs¾ùʧȥ»îÐÔ£¬£¬Pralsetinib(BLU-667)¶ÔG810SÃô¸Ð[6]¡£¡£2021Äê4ÔÂ10ºÅ£¬£¬Loxo Oncology¹«Ë¾±¨µÀ£¬£¬ÔÚ»¼ÕßÖзºÆðRETÈܼÁÇ°ÑØÍ»±äG810λµãºÍÃÅ¿ØÍ»±äV804λµãµÄË«Í»±ä£¬£¬¼°M918TλµãºÍÈܼÁÇ°ÑØÍ»±äG810λµãµÄË«Í»±ä¡£¡£ÌåÍâʵÑéЧ¹ûÏÔʾ£¬£¬RET±¬·¢Ë«Í»±äºó£¬£¬¶ÔSelpercatinib(LOXO-292)ºÍPralsetinib(BLU-667)ÒÖÖƼÁ²»Ãô¸Ð[7]¡£¡£
ͼ4. Ñ¡ÔñÐÔRETÒÖÖƼÁÄÍÒ©ÐÔµÄÄ£Äâ¡£¡£
(ͼƬȪԴÓڲο¼×ÊÁÏ[6])
Õë¶ÔRET¼¤Ã¸ÒÖÖƼÁÒ©Î￪·¢ºÍÐèÇ󣬣¬esballÊÀ²©¹¹½¨Ò»ÏµÁÐBa/F3-RETË«Í»±äµÄ¹¤³Ìϸ°ûÖ꣬£¬ÓÃÓÚÕë¶ÔRET°ÐµãµÄ»¯ºÏÎïɸÐò¼°¶¯ÎïҩЧÆÀ¼Û£¬£¬½Ó´ý¿í´ó¿Í»§×ÉѯÏàÖú¡£¡£
ϸ°ûÖêÁбí
²¿·Öϸ°ûÖêÌåÍâÑéÖ¤Êý¾Ý
²¿·Öϸ°ûÖêÌåÄÚÄ£×ÓÑéÖ¤Êý¾Ý
BLU-667 in Ba/F3-KIF5B-RET Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-V804M Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-V804L Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810C Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810R Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810S Model
²¿·ÖCDXÄ£×ÓÑéÖ¤Êý¾Ý
LOXO-292 in LC-2/ad Model
LOXO-292 in TT Model
²Î¿¼ÎÄÏ×¼°Í¼Æ¬ÈªÔ´£º
1. The importance of the RET gene in thyroid cancer and therapeutic implications. Nature, 2021 May,17:296–306.
2. To Bud or not to Bud: The RET perspective in CAKUT. Pediatr Nephrol. 2014 Apr; 29(4): 597–608.
3. RET Aberrations in Diverse Cancers. Clin Cancer Res; 23(8) April 15, 2017,1988-1997.
4. Curigliano G, et al. 2021 ASCO, Poster 9089.
5.Öйú·ÇСϸ°û·Î°© RET »ùÒòÈÚºÏÁÙ´²¼ì²âר¼Ò¹²Ê¶. Öлª²¡ÀíѧÔÓÖ¾, 2021, 50(6): 583-591.
6. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. Journal of Thoracic Oncology Vol. 2020.15 No. 4: 541-549.
7. Pre-clinical characterization of potent and selective next-generation RET inhibitors. Loxo Oncology at Lilly. Presented at: AACR Annual Meeting 2021.
esballÊÀ²©¹«ÖÚºÅ
Á¢ÒìÒ©ÎïÆÀ¼Û
ÖпÆÒ½ÂöС³ÌÐò
µç»°£º4006 0551 06£¨¹Ù·½ÈÈÏߣ©
0551—67129201£¨¹«Ë¾×ܲ¿£©
꿅᣼www.precedo.cn
µØµã£ººÏ·ÊÊиßÐÂÇøÏ°ÓÑ·¹ú¼Ò¿µ½¡´óÊý¾Ý¹¤ÒµÔ°A6¶°
Copyright © 2021 esballÊÀ²© °æȨËùÓÐ | SEO±êÇ©
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ºÏ·Ê